Contact this trialFirst, we need to learn more about you.
GLP-1 Receptor Agonist
Cagrilintide +2 More for Type 2 Diabetes
Recruiting2 awardsPhase 3
Chapel Hill, North Carolina
This trial will test how well a new medicine called CagriSema helps people with type 2 diabetes to lower their blood sugar and body weight. CagriSema is not yet approved
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service